Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors

Journal of Veterinary Internal Medicine

Volumn 18, Issue 2, 2004, Pages 219-222

  Poirier, V J ^a   Hershey, A E ^a   Burgess, K E ^a   Phillips, B ^a   Turek, M M ^a   Forrest, L J ^a,b   Beaver, L ^a   Vail, D M ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Dog; Malignant histiocytosis; Mammary carcinoma; Osteosarcoma

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; PACLITAXEL;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DOG; HISTOLOGY; HOSPITALIZATION; HYPERSENSITIVITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; NONHUMAN; OSTEOSARCOMA; REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIARRHEA; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MAMMARY NEOPLASMS, ANIMAL; NEUTROPENIA; OSTEOSARCOMA; PACLITAXEL; RECORDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; VOMITING; WISCONSIN;

CANIS FAMILIARIS;

EID: 1642312441     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<219:EATOPT>2.0.CO;2     Document Type: Article

References (24)

1. Wani MC, Taylor HL, Wall MC, et al. Plant antitumor agents: V1. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93: 2325-2327.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;22:665-667.
3. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:348-355.
4. National Cancer Institute. Clinical brochure: Taxol (NSC 125973). Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; 1983:6-12.
5. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational antineoplastic agent. J Natl Cancer Inst 1990;82:1247-1259.
6. Donehower RC, Rowinsky EK, Groshow LB, et al. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987;71: 1171-1177.
7. Wiernik PH, Schwartz EL, Straumann JJ, et al. Phase I clinical and pharmakokinetic study of Taxol. Cancer Res 1987;47:2486-2493.
8. Rowinsky EK, Chaundhry V, Cornblath DR, et al. The neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;15:107.
9. Rowinsly EK, Burke PJ, Karp JE, et al. Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 1989;49:4640-4647.
10. Keia MG, O'Connell JP, Gralla RJ, et al. Phase I study of Taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986;70: 605-607.
11. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991;9:1704.
12. Arbuck SG, Strauss H, Rowinsky EK, et al. A reassessment of the cardiac toxicity associated with Taxol. J Natl Cancer Inst Monog 1993;15:117.
13. Einzig AL, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian cancer. J Clin Oncol 1992;10:1748-1753.
14. Gatzemeier U, Heckmayr M, Neuhauss R, et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung caner. Lung Cancer 1995;12:S101-S106.
15. Swain SM, Honig SF, Tefft MC, et al. A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. Invest New Drugs 1995;13(3):217-222.
16. Alberola V, Rosell R, Gonzalez-Larriba JL, et al. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol 1995;6:S49-S52.
17. Einzig AI, Hochster H, Wiernik PH, et al. A phase II study in patients with malignant melanoma. Invest New Drugs 1991;9(1):59-64.
18. Ogilvie GK, Moore AS, Vail DM, et al. Toxicoses associated with the administration of paclitaxel to dogs with measurable malignancies: A dose escalation study. Veterinary Cancer Society 16th Annual Meeting, Pacific Grove, CA; 1996:28-29.
19. National Cancer Institute. Common toxicity criteria, version 3.0. Available at: http://ctep.cancer.gov. Accessed June 10, 2003.
20. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle using dogs with spontaneously occuring tumors as a model. Clin Cancer Res 1999;5(9):2653-2659.
21. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicity encountered with Taxol. Semin Oncol 1993;20(Suppl 3):1.
22. Ajani JA, Dodd LG, Daugherty K, et al. Taxol-induced soft-tissue injury secondary to extravasation: Characterization by histopathology and clinical course. J Natl Cancer Inst 1994;86:51.
23. Gian VG, Johnson TL, Marsh RW, et al. A phase II trial of paclitaxel in treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J Exp Ther Oncol 1996;1(3):186-190.
24. Patel SR, Papadopoulos NE, Plager C, et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variant. Cancer 1996;78(4):741-744.